Common Warts Global Market Report 2025

The common warts market size has grown strongly in recent years. It will grow from $2.13 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to factors such as increased awareness of skin health, a rising incidence of warts, growing demand for non-invasive procedures, the increasing use of cryotherapy, and the expansion of dermatology clinics.

The common warts market size is expected to see strong growth in the next few years. It will grow to $2.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth during the forecast period can be attributed to factors such as the rising geriatric population, the growing prevalence of viral infections, increased adoption of advanced dermatological therapies, a growing demand for personalized treatments, and a higher consumer preference for homecare solutions. Key trends during this period include advancements in dermatological treatments, expanding healthcare infrastructure, technological innovations in wart removal treatments, greater awareness of available treatment options, and a shift towards minimally invasive treatments.

The rising occurrence of viral infections is expected to drive the growth of the common warts market in the coming years. Viral infections are diseases caused by viruses that enter, multiply, and spread within the body, affecting cells and immune responses. The growing prevalence of these infections is influenced by factors such as globalization, climate change, urbanization, deforestation, and weakened immune systems. Common warts treatments target the human papillomavirus (HPV) responsible for wart formation, providing vital support for viral infection patients by reducing virus transmission, easing discomfort, and promoting healing. This helps prevent complications such as secondary infections or scarring while improving the patient's quality of life. For example, in 2024, the Centers for Disease Control and Prevention reported that, in 2022, the proportion of PCR-confirmed varicella cases rose by 62%, increasing from 29% to 47% over the past five years. Additionally, in January 2023, the National Foundation for Infectious Diseases noted that there are an estimated 14 million new cases of HPV infection annually in the United States. As a result, the rising incidence of viral infections is driving growth in the common warts market.

Key players in the common warts market are focusing on advancing innovative treatments, such as dermatological therapies, to address the growing demand for effective and accessible solutions. These treatments aim to improve patient outcomes and expand market presence in the dermatology sector. Dermatological therapies refer to treatments for skin conditions, including infections, inflammations, and disorders. For instance, in May 2024, Verrica Pharmaceuticals, a U.S.-based pharmaceutical company, entered into a licensing agreement with Torii Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company. This collaboration is designed to fund a global Phase 3 clinical trial for YCANTH, a treatment for common warts. The agreement supports the late-stage development of YCANTH, helping it reach a broader global market. Torii Pharmaceuticals will contribute financial resources to support the study, which will enhance both companies' dermatology portfolios and expand their international presence.

In June 2023, Vial, a U.S.-based clinical trial management organization, partnered with Nielsen BioSciences to conduct a Phase 3 clinical trial for CANDIN. This collaboration is aimed at further developing CANDIN as a potential treatment for common warts by evaluating its safety and efficacy. Nielsen BioSciences, a U.S.-based biotechnology company specializing in immune-based therapies, is helping advance CANDIN as a promising treatment option.

Major players in the market are AbbVie Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Limited, Perrigo Company plc, Holland & Barrett International Limited, Prestige Consumer Healthcare Inc., Maruho Co. Ltd., Novan Inc., X4 Pharmaceuticals Inc., Aclaris Therapeutics Inc., Verrica Pharmaceuticals Inc., RXi Pharmaceuticals Corporation, Scholl’s Wellness Company, Nielsen BioSciences Inc., Cassiopea S.p.A., Orgenesis Inc., KinoPharma Inc., Naturasil, Veradermics Inc., KinoPharma Co. Ltd.

North America was the largest region in the common warts market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in common warts report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the common warts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Common warts are non-cancerous skin growths caused by the human papillomavirus (HPV). They typically appear on the hands, fingers, and other areas, acting as a defense mechanism for the body in response to the viral infection.

The main treatment options for common warts include cryotherapy, laser treatment, electrosurgery, and topical medications. Cryotherapy is a treatment that uses extreme cold, usually liquid nitrogen, to freeze and destroy abnormal tissue. These treatments are provided across various patient demographics, including children, adults, and the elderly. Treatment approaches vary depending on the stage of the condition, with options tailored for the initial, moderate, or severe stages. These treatments are administered in various settings, such as hospitals, dermatology clinics, and home care.

The common warts market research report is one of a series of new reports that provides common warts market statistics, including the common warts industry global market size, regional shares, competitors with the common warts market share, detailed common warts market segments, market trends, and opportunities, and any further data you may need to thrive in the common warts industry. These common warts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The common warts market consists of revenues earned by entities by providing services such as telemedicine consultations, therapy services, and surgical excision. The market value includes the value of related goods sold by the service provider or included within the service offering. The common warts market also includes sales of over-the-counter (OTC) treatments, prescription medications, and medical devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.